These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 36253033)

  • 41. Protocol for Compass: a randomised controlled trial of primary HPV testing versus cytology screening for cervical cancer in HPV-unvaccinated and vaccinated women aged 25-69 years living in Australia.
    Canfell K; Saville M; Caruana M; Gebski V; Darlington-Brown J; Brotherton J; Heley S; Castle PE
    BMJ Open; 2018 Jan; 8(1):e016700. PubMed ID: 29374658
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prediction of recurrence after treatment for high-grade cervical intraepithelial neoplasia: the role of human papillomavirus testing and age at conisation.
    Verguts J; Bronselaer B; Donders G; Arbyn M; Van Eldere J; Drijkoningen M; Poppe W
    BJOG; 2006 Nov; 113(11):1303-7. PubMed ID: 16978225
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The performance of human papillomavirus DNA detection with type 16/18 genotyping by hybrid capture in primary test of cervical cancer screening: a cross-sectional study in 10,669 Chinese women.
    Zhao X; Wu Q; Wang X; Fu Y; Zhang X; Tian X; Cheng B; Lu B; Yu X; Lan S; Lu W; Ma D; Cheng X; Xie X
    Clin Microbiol Infect; 2018 Dec; 24(12):1322-1327. PubMed ID: 29518562
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Long term duration of protective effect for HPV negative women: follow-up of primary HPV screening randomised controlled trial.
    Elfström KM; Smelov V; Johansson AL; Eklund C; Nauclér P; Arnheim-Dahlström L; Dillner J
    BMJ; 2014 Jan; 348():g130. PubMed ID: 24435414
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Real-world effectiveness of primary screening with high-risk human papillomavirus testing in the cervical cancer screening programme in China: a nationwide, population-based study.
    Zhao Y; Bao H; Ma L; Song B; Di J; Wang L; Gao Y; Ren W; Wang S; Wang HJ; Wu J
    BMC Med; 2021 Jul; 19(1):164. PubMed ID: 34261463
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Dual staining for p16/Ki-67 to detect high-grade cervical lesions: Results from the Screening Triage Ascertaining Intraepithelial Neoplasia by Immunostain Testing study.
    El-Zein M; Gotlieb W; Gilbert L; Hemmings R; Behr MA; Franco EL;
    Int J Cancer; 2021 Jan; 148(2):492-501. PubMed ID: 32781481
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cost-Effectiveness of Primary HPV Testing, Cytology and Co-testing as Cervical Cancer Screening for Women Above Age 30 Years.
    Jin XW; Lipold L; Foucher J; Sikon A; Brainard J; Belinson J; Schramm S; Nottingham K; Hu B; Rothberg MB
    J Gen Intern Med; 2016 Nov; 31(11):1338-1344. PubMed ID: 27418345
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effect of Sequential Rounds of Cervical Cancer Screening on Management of HPV-positive Women: A 15-year Population-based Cohort Study from China.
    Xu XQ; Rezhake R; Hu SY; Chen F; Zhang X; Pan QJ; Zhang WH; Ma JF; Qiao YL; Zhao FH; Cruickshank M
    Cancer Prev Res (Phila); 2021 Mar; 14(3):363-372. PubMed ID: 33303694
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A pilot study of HPV DNA and cytology testing in 50,159 women in the routine Mexican Social Security Program.
    Lazcano-Ponce E; Lörincz AT; Salmerón J; Fernández I; Cruz A; Hernández P; Mejia I; Hernández-Avila M
    Cancer Causes Control; 2010 Oct; 21(10):1693-700. PubMed ID: 20617376
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Use of a high-risk human papillomavirus DNA test as the primary test in a cervical cancer screening programme: a population-based cohort study.
    Zorzi M; Del Mistro A; Farruggio A; de'Bartolomeis L; Frayle-Salamanca H; Baboci L; Bertazzo A; Cocco P; Fedato C; Gennaro M; Marchi N; Penon MG; Cogo C; Ferro A
    BJOG; 2013 Sep; 120(10):1260-7; discussion 1267-8. PubMed ID: 23786222
    [TBL] [Abstract][Full Text] [Related]  

  • 51. High-Risk HPV Testing in Primary Screening for Cervical Cancer in the Public Health System, São Paulo, Brazil.
    Levi JE; Martins TR; Longatto-Filho A; Cohen DD; Cury L; Fuza LM; Villa LL; Eluf-Neto J
    Cancer Prev Res (Phila); 2019 Aug; 12(8):539-546. PubMed ID: 31189569
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Detection Rate of High-Grade Cervical Neoplasia and Cost-Effectiveness of High-Risk Human Papillomavirus Genotyping with Reflex Liquid-based Cytology in Cervical Cancer Screening.
    Tay SK; Lin LE; Goh RC
    Ann Acad Med Singap; 2017 Jul; 46(7):267-273. PubMed ID: 28821890
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Triaging Pap cytology negative, HPV positive cervical cancer screening results with p16/Ki-67 Dual-stained cytology.
    Petry KU; Schmidt D; Scherbring S; Luyten A; Reinecke-Lüthge A; Bergeron C; Kommoss F; Löning T; Ordi J; Regauer S; Ridder R
    Gynecol Oncol; 2011 Jun; 121(3):505-9. PubMed ID: 21420158
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Primary cervical cancer screening with HPV testing compared with liquid-based cytology: results of round 1 of a randomised controlled trial -- the HPV FOCAL Study.
    Ogilvie GS; Krajden M; van Niekerk DJ; Martin RE; Ehlen TG; Ceballos K; Smith LW; Kan L; Cook DA; Peacock S; Stuart GC; Franco EL; Coldman AJ
    Br J Cancer; 2012 Dec; 107(12):1917-24. PubMed ID: 23169286
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evaluating the performance of three different cervical cancer screening modalities in a large prospective population-based cohort.
    Song F; Du H; Xiao A; Wang C; Huang X; Liu Z; Zhao M; Men H; Wu R
    J Infect Public Health; 2020 Nov; 13(11):1780-1786. PubMed ID: 32919932
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Performance and Diagnostic Accuracy of Human Papillomavirus Testing on Self-Collected Urine and Vaginal Samples in a Referral Population.
    Cho HW; Hong JH; Min KJ; Ouh YT; Seong SJ; Moon JH; Cho SH; Lee JK
    Cancer Res Treat; 2021 Jul; 53(3):829-836. PubMed ID: 33421987
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Informed cytology for triaging HPV-positive women: substudy nested in the NTCC randomized controlled trial.
    Bergeron C; Giorgi-Rossi P; Cas F; Schiboni ML; Ghiringhello B; Dalla Palma P; Minucci D; Rosso S; Zorzi M; Naldoni C; Segnan N; Confortini M; Ronco G
    J Natl Cancer Inst; 2015 Feb; 107(2):. PubMed ID: 25568167
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparison of cervical cancer screening strategies incorporating different combinations of cytology, HPV testing, and genotyping for HPV 16/18: results from the ATHENA HPV study.
    Cox JT; Castle PE; Behrens CM; Sharma A; Wright TC; Cuzick J;
    Am J Obstet Gynecol; 2013 Mar; 208(3):184.e1-184.e11. PubMed ID: 23174289
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparison of human papillomavirus genotyping and cytology triage, COMPACT Study: Design, methods and baseline results in 14 642 women.
    Aoyama-Kikawa S; Fujita H; Hanley SJB; Kasamo M; Kikuchi K; Torigoe T; Matsuno Y; Tamakoshi A; Sasaki T; Matsuura M; Kato Y; Dong P; Watari H; Saito T; Sengoku K; Sakuragi N
    Cancer Sci; 2018 Jun; 109(6):2003-2012. PubMed ID: 29660849
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The impact of age and high-risk human papillomavirus (hrHPV) status on the prevalence of high-grade cervical intraepithelial neoplasia (CIN2+) in women with persistent hrHPV-positive, cytology-negative screening samples: a prospective cohort study.
    Tidy JA; Lyon R; Ellis K; Macdonald M; Palmer JE
    BJOG; 2020 Sep; 127(10):1260-1267. PubMed ID: 32279427
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.